Researchers estimate the number of people globally living with chronic obstructive pulmonary disease (COPD) will hit 600 million by 2050. There are certain risk factors for COPD, including obesity and ...

Medication nonadherence among people with chronic obstructive pulmonary disease (COPD) is a result of affordability and lack of knowledge about medications, among other factors, and leads to increased ...

For patients with chronic obstructive pulmonary disease (COPD), the Global Initiative on Obstructive Lung Disease recommends long-term term pharmacologic and nonpharmacologic therapies based on each ...

SGLT2 inhibitors and GLP-1 receptor agonists were associated with fewer exacerbations of COPD in adults with type 2 diabetes. There was little difference between SGLT2 inhibitors and GLP-1 receptor ...

The U.S. Food and Drug Administration on Tuesday approved the first generic Symbicort drug used to treat asthma and chronic obstructive pulmonary disease (COPD), which are two common pulmonary health ...

Recent medical research reveals promising developments in the treatment of patients suffering from both diabetes and chronic obstructive pulmonary disease. The study, involving nearly 394,000 adults, ...

Certain glucose-lowering drugs were linked to fewer moderate or severe COPD exacerbations in adults with type 2 diabetes Study: Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary ...

The Food and Drug Administration on Friday rejected Sunovion Pharmaceuticals’ treatment for chronic obstructive pulmonary disease. The late-stage drug is intended to serve as a long-term treatment for ...

Of the hundreds of drugs that entered the U.S. market in 2024, GoodRx has named 19 of them as the most notable. Note: The chronological list does not include December approvals. 1. Dupixent (dupilumab ...

Delve into the field of pulmonary hypertension as GSK places a $950M bet on 35Pharma's candidate HS235 following the footsteps of Winrevair.